Amgen Inc/ US0311621009 /
21/08/2024 16:47:24 | Chg. - | Volume | Bid13:54:49 | Ask13:54:49 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
295.85EUR | - | 12 Turnover: 3,543.20 |
300.15Bid Size: 30 | 302.35Ask Size: 30 | 162.37 bill.EUR | - | - |
GlobeNewswire
15/08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
12/08
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
05/08
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
22/07
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
02/07
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire
27/06
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire
27/06
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...
GlobeNewswire
25/06
Arthritis Foundation Launches Carolina Hills Classic Bike Tour, Coming June 2025
GlobeNewswire
20/06
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...